Literature DB >> 9811741

Occult systemic infection and persistent simian immunodeficiency virus (SIV)-specific CD4(+)-T-cell proliferative responses in rhesus macaques that were transiently viremic after intravaginal inoculation of SIV.

M B McChesney1, J R Collins, D Lu, X Lu, J Torten, R L Ashley, M W Cloyd, C J Miller.   

Abstract

The intact cervicovaginal mucosa is a relative barrier to the sexual transmission of human immunodeficiency virus type 1 (HIV-1). In the simian immunodeficiency virus (SIV) macaque model of HIV infection, seronegative transient viremia (STV; virus isolation positive followed by repeated negative cultures) occurs after intravaginal inoculation of a low dose of pathogenic SIVmac251 (C. J. Miller, M. Marthas, J. Torten, N. Alexander, J. Moore, G. Doncel, and A. Hendrickx, J. Virol. 68:6391-6400, 1994). Thirty-one adult female macaques that had been inoculated intravaginally with pathogenic SIVmac251 became transiently viremic. One monkey that had been culture negative for a year after SIV inoculation became persistently viremic and developed simian AIDS. No other STV monkey developed persistent viremia or disease. Results of very sensitive assays showed that 6 of 31 monkeys had weak SIV-specific antibody responses. SIV-specific antibodies were not detected in the cervicovaginal secretions of 10 STV monkeys examined. Twenty of 26 monkeys had lymphocyte proliferative responses to p55(gag) and/or gp130(env) antigens; 3 of 6 animals, including the monkey that became persistently viremic, had detectable cytotoxic T-lymphocyte (CTL) responses to SIV. At necropsy, lymphoid tissues and vaginal mucosa were virus culture negative, but in 10 of 10 animals, SIV provirus was detected by PCR using gag-specific primer pairs. Fifty percent of the PCR-positive tissue samples were also positive for SIV gag RNA by reverse transcriptase PCR. Thus, transient viremia following intravaginal inoculation of pathogenic SIV is associated with persistent, systemic infection, either latent or very low level productive. Atypical immune responses, characterized by lymphocyte proliferation and some CTL responses in the absence of conventionally detectable antibodies, develop in transiently viremic monkeys.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811741      PMCID: PMC110525     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Highly sensitive enhanced chemiluminescence immunodetection method for herpes simplex virus type 2 Western immunoblot.

Authors:  J Dalessio; R Ashley
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

2.  Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus.

Authors:  M D Daniel; N L Letvin; P K Sehgal; G Hunsmann; D K Schmidt; N W King; R C Desrosiers
Journal:  J Gen Virol       Date:  1987-12       Impact factor: 3.891

3.  Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals.

Authors:  S Sutjipto; N C Pedersen; C J Miller; M B Gardner; C V Hanson; A Gettie; M Jennings; J Higgins; P A Marx
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

4.  Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission.

Authors:  P Putkonen; B Mäkitalo; D Böttiger; G Biberfeld; R Thorstensson
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  Silent HIV infections.

Authors:  W A Haseltine
Journal:  N Engl J Med       Date:  1989-06-01       Impact factor: 91.245

Review 6.  Immunologic and pathologic manifestations of the infection of rhesus monkeys with simian immunodeficiency virus of macaques.

Authors:  N L Letvin; N W King
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

7.  Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV.

Authors:  M L Marthas; S Sutjipto; J Higgins; B Lohman; J Torten; P A Luciw; P A Marx; N C Pedersen
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

8.  Rhesus macaques inoculated with molecularly cloned simian immunodeficiency virus.

Authors:  M L Marthas; B Banapour; S Sutjipto; M E Siegel; P A Marx; M B Gardner; N C Pedersen; P A Luciw
Journal:  J Med Primatol       Date:  1989       Impact factor: 0.667

9.  Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay.

Authors:  B L Lohman; J Higgins; M L Marthas; P A Marx; N C Pedersen
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

10.  Human immunodeficiency virus infection elicits early antibody not detected by standard tests: implications for diagnostics and viral immunology.

Authors:  E M Race; K M Ramsey; H L Lucia; M W Cloyd
Journal:  Virology       Date:  1991-10       Impact factor: 3.616

View more
  38 in total

Review 1.  A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds.

Authors:  Thomas J Hope; Jeanne M Marrazzo
Journal:  AIDS Res Hum Retroviruses       Date:  2015-11       Impact factor: 2.205

2.  Antiviral antibodies are necessary for control of simian immunodeficiency virus replication.

Authors:  Christopher J Miller; Meritxell Genescà; Kristina Abel; David Montefiori; Donald Forthal; Kristen Bost; Jun Li; David Favre; Joseph M McCune
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

3.  Induction of potent local cellular immunity with low dose X4 SHIV(SF33A) vaginal exposure.

Authors:  Silvana Tasca; Lily Tsai; Nataliya Trunova; Agegnehu Gettie; Mohammed Saifuddin; Rudolf Bohm; Lisa Chakrabarti; Cecilia Cheng-Mayer
Journal:  Virology       Date:  2007-06-15       Impact factor: 3.616

Review 4.  Understanding the "lucky few": the conundrum of HIV-exposed, seronegative individuals.

Authors:  Barbara L Shacklett
Journal:  Curr HIV/AIDS Rep       Date:  2006-02       Impact factor: 5.071

5.  Differential selection of specific human immunodeficiency virus type 1/JC499 variants after mucosal and parenteral inoculation of chimpanzees.

Authors:  Qing Wei; Patricia N Fultz
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 6.  Targeting early infection to prevent HIV-1 mucosal transmission.

Authors:  Ashley T Haase
Journal:  Nature       Date:  2010-03-11       Impact factor: 49.962

7.  Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3.

Authors:  Pushpa Jayaraman; Tuofu Zhu; Lynda Misher; Deepika Mohan; LaRene Kuller; Patricia Polacino; Barbra A Richardson; Helle Bielefeldt-Ohmann; David Anderson; Shiu-Lok Hu; Nancy L Haigwood
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Depo-provera treatment does not abrogate protection from intravenous SIV challenge in female macaques immunized with an attenuated AIDS virus.

Authors:  Meritxell Genescà; Michael B McChesney; Christopher J Miller
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

9.  Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1.

Authors:  Brandon F Keele; Hui Li; Gerald H Learn; Peter Hraber; Elena E Giorgi; Truman Grayson; Chuanxi Sun; Yalu Chen; Wendy W Yeh; Norman L Letvin; John R Mascola; Gary J Nabel; Barton F Haynes; Tanmoy Bhattacharya; Alan S Perelson; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  J Exp Med       Date:  2009-05-04       Impact factor: 14.307

10.  Acute mucosal pathogenesis of feline immunodeficiency virus is independent of viral dose in vaginally infected cats.

Authors:  Kristina E Howard; Stacie K Reckling; Erin A Egan; Gregg A Dean
Journal:  Retrovirology       Date:  2010-01-19       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.